Following the announcement of our partnership with eMQT, Shivom asks the community to take a moment to reflect on the devastating genetic disorder Sickle Cell Disease (SCD)
SCD is a blood disease and particularly common in people with an African or Caribbean family background. Patients with SCD produce irregular shaped red blood cells that can cause complications because they don’t live as long as healthy blood cells and can’t carry enough oxygen around the body. Due to their shape, these blood cells can get stuck inside smaller blood vessels. This keeps blood from flowing and can cause pain and severe damage to parts of the body, ultimately leading to a reduced life expectancy.
We are inviting patients, physicians, and researchers to share their experiences with SCD on our social media channels.
Follow us, tweet at us @ProjectShivom, and use the hashtag #SickleCellAwareness OR you can send us your story to email@example.com
Read more about our work with SCD and our partnership with eMQT here
Moving Forward with Diabetes Pilot in India
Towards the end of September our CEO, Henry Ines, and our Co-Founder and CSO, Dr. Axel Schumacher will again head to India to begin our Type II diabetes (T2D) pilot study in the state of Andhra Pradesh, located in the south-eastern part of the subcontinent. Together with our Indian partners, including a diagnostics clinic and local doctors, we will initiate the collection of DNA samples from diabetes patients and matched control subjects. Among others, the work will also involve setting up recruitment, sample logistics, educational programs, and standard operating procedures for the pilot and further projects.Our pilot program serves to bring precision medicine studies to the next era. The study will not only aim at finding genotypes that are specific to Indian sub populations but help diagnose and treat the disease. Collected data will help to further our blockchain platform, provide a proof of concept of assigning digital identities for the local population, and provide data ownership to study participants. By using state-of-the-art AI algorithms, Shivom and our partners will work towards the identification of biomarkers for accurate classification of patient subgroups and diabetes management apps within our platform.
What’s New with Our Platform?
We are thrilled by the high-interest shown by our community to test one of our first modules. Please stay tuned for more information regarding the release date and details for logging into the test module.
We look forward to providing the community with more updates next month and hearing your SCD stories.
As always, we thank you for your continued support and dedication.